"The study demonstrated the safety of long-term nitazoxanide exposure
in patients with chronic hepatitis C. Importantly, this data suggests that
thiazolides have an interferon-like mechanism and as a class may have a
role as single agent therapy in some patients," said Dr. Emmet Keeffe,
chief medical officer for Romark and co-author of the study.
-- An oral presentation by Brent Korba, Ph.D. of, Georgetown University
Medical Center, described preclinical studies showing that treatment of
cells harboring HCV replicons with nitazoxanide or its primary
metabolite, tizoxanide, does not induce viral mutations conferring
resistance to nitazoxanide, tizoxanide, interferon, ribavirin or 2'C-
methyl cytidine (a polymerase inhibitor). The presentation, titled,
"Studies of the Potential for Resistance to Nitazoxanide or Tizoxanide
in HCV-Containing Replicon Cell Lines," also demonstrated that
treatment of HCV replicon cells with tizoxanide potentiates the
antiviral effect of subsequent treatment with interferon (8-fold
decrease in concentration of interferon required to inhibit virus
replication by 90%).
"Data presented in each of these communications has provided important information in guiding the ongoing clinical development of nitazoxanide," said Dr. Rossignol.
Romark is currently enrolling patients for two U.S. clinical trials studying nitazoxanide for the treatment of hepatitis C genotype 1. For more information please visit please visit http://www.romarktrials.com or http://www.clinicaltrials.gov and enter the search term "nitazoxanide hepatitis United States."
Nitazoxanide belongs to a new class of small molecule cell signaling
modulators (CSMs) called the thiazolides. Like interferons, thiaz
|SOURCE Romark Laboratories|
Copyright©2008 PR Newswire.
All rights reserved